Email this article 
Current feasibility of endocrine therapy for breast cancer
- Authors: Vysotskaya I.V.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University
- Issue: No 1 (2011)
- Pages: 46-49
- Section: MAMMOLOGY. TREATMENT
- Published: 25.02.2011
- URL: https://ojrs.abvpress.ru/ojrs/article/view/142
- DOI: https://doi.org/10.17650/1994-4098-2011-0-1-46-49
- ID: 142
Cite item
Full Text
Abstract
The paper considers the current feasibility of endocrine therapy for breast cancer (BC). It presents trials of the efficacy of fulvestrant in the treatment of patients with BC. Practically all clinical trials have demonstrated that the drug is well tolerated, without causing any significant systemic estrogen-like effects, as well as complications associated with the use of aromatase inhibitors.
Keywords
About the authors
I. V. Vysotskaya
I.M. Sechenov First Moscow State Medical University
Author for correspondence.
Email: vysotskaya.irina@mail.ru
Russian Federation
References
Supplementary files
